Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Oct. 25 Company Quick Takes: Astellas gets European approval for AML therapy; plus Acorda, Amgen, Illumina-PacBio and Qpex-Brii

Astellas’ Xospata wins AML approval in Europe
The European Commission has approved Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) as a monotherapy for relapsed or refractory acute myelogenous leukemia with an FLT3 Mutation. The oral

Read the full 346 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE